Arbutus Biopharma Corp (ABUS) vs Aktis Oncology, Inc. (AKTS)

A side-by-side comparison of Arbutus Biopharma Corp and Aktis Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Arbutus Biopharma Corp logo
ABUS
Arbutus Biopharma Corp
$923M
$4.67HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Aktis Oncology, Inc. logo
AKTS
Aktis Oncology, Inc.
$989M
$18.52HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ABUS vs AKTS

growth of $100 · dividends reinvested · last 1y
ABUS -0.8% (-0.8%/yr)AKTS -17.3% (-17.3%/yr)ABUS compounded faster over this window
80100120140Start $100$99$83
ABUS AKTS

ABUS vs AKTS: by the numbers

  • •AKTS is the larger company ($989M vs $923M market cap).
  • •ABUS is profitable (84.23% net margin) while AKTS runs a net loss (-727.04%).

Metrics side by side

Valuation

MetricABUSAKTS
P/E ratio5.98N/A
Forward P/E6.31N/A
P/S ratio5.0898.32
P/B ratio3.572.04
EV / EBITDA6.16N/A

Profitability

MetricABUSAKTS
Gross margin99.98%100.00%
Operating margin-192.08%-1149.52%
Net margin84.23%-727.04%
ROE59.16%-15.09%
ROIC54.39%-16.54%

Growth (annualized)

MetricABUSAKTS
Revenue CAGR (5Y)85.17%N/A
Total return CAGR (5Y)2.19%N/A

Frequently asked

Is ABUS or AKTS more profitable?
ABUS runs the higher net margin — ABUS at 84.23% versus AKTS at -727.04%.

Go deeper

Full ABUS analysisFull AKTS analysisInteractive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratioArbutus Biopharma ROEAktis Oncology ROEArbutus Biopharma operating marginAktis Oncology operating marginArbutus Biopharma revenue growthAktis Oncology revenue growthArbutus Biopharma free cash flowAktis Oncology free cash flow

Arbutus Biopharma & Aktis Oncology appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.